ImmunoGen, Inc. Announces Conference Call to Discuss its Second Quarter Fiscal Year 2011 Financial Results

WALTHAM, Mass.--(BUSINESS WIRE)-- ImmunoGen, Inc. (NASDAQ:IMGN), a biotechnology company that develops targeted antibody-based anticancer products using its antibody expertise and Targeted Antibody Payload (TAP) technology, today announced that the Company will host a conference call at 4:30 p.m. ET on Thursday, January 27, 2011, to discuss ImmunoGen's financial results for the three-month period ended December 31, 2010 – the second quarter of the Company’s 2011 fiscal year. Management also will provide an update on the Company.

To access the live call by phone, dial 913-312-0379. Passcode: 7227748. The call also may be accessed through the Investor Information section of the Company's website, http://www.immunogen.com. Following the live webcast, a replay of the call will be available at the same location through February 3, 2011.

About ImmunoGen, Inc.

ImmunoGen, Inc. develops targeted anticancer therapeutics using the Company's expertise in tumor biology, monoclonal antibodies and potent cancer-cell killing agents. The Company's TAP technology uses monoclonal antibodies to deliver one of ImmunoGen's proprietary cancer-cell killing agents specifically to tumor cells. There are currently seven TAP compounds in the clinic, with a wealth of clinical data reported with the technology. ImmunoGen’s collaborative partners include Amgen, Bayer Schering Pharma, Biogen Idec, Biotest, Genentech (a member of the Roche Group), Novartis, and sanofi-aventis. The most advanced compound using ImmunoGen's TAP technology, trastuzumab-DM1 (T-DM1), is in Phase III testing through the Company's collaboration with Genentech. More information about ImmunoGen can be found at www.immunogen.com.



CONTACT:

For Investors:
ImmunoGen, Inc.
Carol Hausner, 781-895-0600
[email protected]
Executive Director, Investor Relations and Corporate Communications
or
For Media:
The Yates Network
Barbara Yates, 781-258-6153

KEYWORDS:   United States  North America  Massachusetts

INDUSTRY KEYWORDS:   Health  Biotechnology  Oncology  Pharmaceutical

MEDIA:

Suggested Articles

Teva is reportedly going for a moonshot with a $15 billion drug offer to settle its opioid cases. It's a plan that might just work, one analyst said.

CSL has sued a former exec who its says stole thousands of key documents as he left for competitor Pharming.

Influential U.S. cost watchdog ICER gave its blessing to Johnson & Johnson and Amarin's CV drugs. But there's a big catch for both meds.